Diagnostic and prognostic markers in infants with disseminated neuroblastoma: A retrospective analysis from the Italian Cooperative Group for Neuroblastoma

Medical Science Monitor

Volumn 15, Issue 1, 2009, Pages

  Di Cataldo, Andrea ^a   Dau, Daniela ^b   Conte, Massimo ^b   Parodi, Stefano ^b   De Bernardi, Bruno ^b   Giuliano, Maria ^c   Pession, Andrea ^d   Viscardi, Elisabetta ^e   Luksch, Roberto ^f   Castellano, Aurora ^g   Bertuna, Gregoria ^a   Haupt, Riccardo ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Infant; Metastasis; MYCN; Neuroblastoma; Stage 4s

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; ETOPOSIDE; FERRITIN; HOMOVANILLIC ACID; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; NEURON SPECIFIC ENOLASE; VANILMANDELIC ACID; VINCRISTINE;

ARTICLE; BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 1P; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); DRUG FATALITY; DRUG MEGADOSE; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENE AMPLIFICATION; GESTATIONAL AGE; HEMATOPOIETIC STEM CELL; HISTOLOGY; HUMAN; HUMAN TISSUE; INFANT; ITALY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYCN GENE; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RETROSPECTIVE STUDY; SCINTIGRAPHY; SURVIVAL RATE; TETRAPLOIDY; THROMBOCYTOPENIA; ULTRASOUND; URINARY EXCRETION;

BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, PAIR 1; FERRITINS; GENETIC MARKERS; HOMOVANILLIC ACID; HUMANS; INFANT; INFANT, NEWBORN; ITALY; L-LACTATE DEHYDROGENASE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VANILMANDELIC ACID;

EID: 58649083680     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Caron H, Pearson ADJ: Neuroblastoma. In: Voûte PA, Barrett A, Stevens MCG, Caron HN (eds.), Cancer in children. Oxford: Oxford University Press; 2005; 323-52
2. De Bernardi B, Pianca C, Boni L et al: Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Cancer, 1992; 70: 1625-33
3. Brodeur GM, Pritchard J, Berthold F et al: Revision of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol, 1993; 11: 1466-77
4. Strother D, Shuster JJ, McWilliams N et al: Results of Pediatric Oncology Group protocol 8104 for infants with stages D and DS Neuroblastoma. J Pediatr Hematol Oncol, 1995; 17: 254-59
5. Katzenstein HM, Bowman LC, Brodeur GM et al: Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol, 1998; 16: 2007-17
6. Nickerson HJ, Matthay KK, Seeger RC et al: Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol, 2000; 18: 477-86
7. Schmidt ML, Lukens JN, Seeger C et al: Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol, 2000; 18: 1260-68
8. Hero B, Simon T, Horz S, Berthold F: Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis? Med Pediatr Oncol, 2000; 35: 683-87
9. Minard V, Hartmann O, Peyroulet MC et al: Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: result of the French Society of Pediatric Oncology. Br J Cancer, 2000; 83: 973-79
10. Schleiermacher G, Rubie H, Hartmann O et al: Treatment of stage 4s neuroblastoma. Report of 10 years' experience of the French Society of Paediatric Oncology. Br J Cancer, 2003; 89: 470-76
11. Rubie H, Hartmann O, Michon J et al: N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Sociétè Francaise d'Oncologie Pédiatrique. J Clin Oncol, 1997; 15: 1171-82
12. Caron H, Van Sluis P, De Kraker J et al: Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patients with neuroblastoma. New Engl J Med, 1996; 12: 225-30
13. Giaretti W: Ploidy and proliferation evaluated by flow cytometry. An overview of techniques and impact in oncology. Tumori, 1991; 77: 403-19
14. Zeltzer PM, Marangos PJ, Parma AM et al: Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet, 1983; 322: 361-63
15. Schuster JJ, McWilliams NB, Castleberry R et al: Serum lactate dehydrogenase in childhood neuroblastoma. Am J Clin Oncol, 1992; 15: 295-303
16. Conte M, Parodi S, De Bernardi B et al: Neuroblastoma in adolescents: the Italian experience. Cancer, 2006; 106: 1409-17
17. Baussano I, Maule MM, Dana E et al: Expected number of childhood cancers in Italy from 2001 to 2015. Haematologica, 2007; 92: 1258-61
18. Claudiani F, Stimamiglio P, Bertolazzi L et al: Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nucl Med, 1995; 39: 21-24
19. Marchese N, Canini S, Fabi L, Famularo L: Paediatric reference values for urinary catecholamine metabolites evaluated by high performance liquid chromatography and electrochemical detection. Eur J Clin Chem Clin Biochem, 1997; 35: 533-37
20. Hsu LL, Evans AE, D'Angio GJ: Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol, 1996; 27: 521-28
21. Zambrano E, Reyes-Múgica M: Hormonal activity may predict aggressive behavior in neuroblastoma. Pediatr Dev Pathol, 2002; 5: 190-99
22. Strenger V, Kerbl R, Dornbusch HJ et al: Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer, 2007; 48: 504-9
23. Parodi S, Papio F, Haupt R et al: The prognostic role of urinary catecholamines in infants with disseminated neuroblastoma may be mediated by MYCN amplification. Pediatr Blood Cancer, 2007; 48: 593
24. De Bernardi B, Nicolas B, Boni L et al: Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-operative Group for Neuroblastoma. J Clin Oncol, 2003; 21: 1592-601